Anti-CD38-Based Quadruplet Improves Outcomes in Transplant-Ineligible Myeloma

[ad_1]

(MedPage Today) — Daratumumab (Darzalex) plus the standard triplet of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) significantly improved clinical outcomes versus VRd alone in patients with transplant-ineligible or…

[ad_2]

Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/114159

Author :

Publish date : 2025-02-10 21:08:40

Copyright for syndicated content belongs to the linked Source.